Advanced Proteome Therapeutics Corporation has prepared several molecules using its patent-pending technologies, which represent the first of several series that the Company has conceived as potential anti-cancer agents, each of which has its own individual attributes for drug development. In the first round of testing by APC and its collaborators, all members of the first series exhibited high affinity for specific cancer cells and no obvious toxic effects on healthy cells. The unmodified protein by itself demonstrated the ability to retard tumor growth, and a conjugate of the protein prepared by APC was shown to concentrate in tumors.

Following on these tests, the company has now discovered that two members of the first series, which have been selected for further testing in animal models of cancer, have demonstrated statistically significant retardation of tumor growth in mice and possess higher affinity than the unmodified protein toward specific cancer cells. These positive findings suggest that its chemical modifications to the protein, which in unmodified form activates animal immune systems to destroy tumor cells, may be used to enhance the activity of the protein itself, and achieve therapeutic benefits for the Company's proprietary molecular assets. In line with company plans to select a lead member of at least three series, with all deliberate speed, for advanced preclinical development and deal-making, testing has now begun on the second series of protein modifications and testing on the third series is expected to begin shortly.

The company will carry out animal studies over the next few months to optimize the properties of its most effective and commercially attractive candidates. This process is expected to result in the selection of candidates with the mix of properties to speed development. The Company plans, concurrently, to seek out corporate Partners in the pharmaceutical industry for joint efforts or licensing deals, which would support company programs and advance eligible candidates toward clinical trials as rapidly as possible according to strategic plans.

Advanced Proteome Therapeutics has been applying its enabling Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent.

To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.